The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients
Table 1
The basic characteristics of the studies with thiazolidinediones
in HIV-infected, HAART-treated patients. HAART = highly active antiretroviral therapy, IR = insulin resistance,
LA = lipoatrophy, OGTT = oral glucose tolerance test, LD = lipodystrophy.
Rosiglitazone 4 mg/d, or metformin 2 g/d, or rosiglitazone + metformin, or placebo
16 weeks
IR (fasting insulin 15 IU/ml, or 2 h insulin [OGTT] 75 IU/ml, or 2 h glucose [OGTT] 7.7 mmol/L and fasting insulin 10 IU/ml) and
self-reported changes in body fat (including increased waist-to-hip ratio or
waist circumference)